The treatment of tuberculosis in HIV-infected persons

AIDS

Volumn 13, Issue 4, 1999, Pages 435-445

  Pozniak, Anton L ^a   Miller, Rob ^b   Ormerod, L Peter ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL BLACKBURN HOSPITAL   (United Kingdom)

Author keywords

AIDS; Antiviral therapy; Drug interactions; HIV; Treatment; Tuberculosis

Indexed keywords

AIDS RELATED COMPLEX; EDITORIAL; HUMAN; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HUMANS; TUBERCULOSIS;

EID: 0033545445     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199903110-00001     Document Type: Article

References (99)

1. Raviglione MC, Snider DF, Kochi A: Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995, 72:213-220.
2. Schwoebel V, Delmas MC, Hamers F, Alix J, Brunet JB, National Coordinators of AIDS Surveillance: Tuberculosis as an AIDS-defining disease in Europe. Clin Microbiol Infect 1996, 1:286-288.
3. Dolin PL, Raviglione MC, Kochi A: Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994, 72:213-220.
4. Yanar H, Uthaivoravit W, Panich V, et al.: Rapid increase in HIV-related tuberculosis, Chiang Rai, Thailand, 1990-1994. AIDS 1996, 10:527-531.
5. Centers for Disease Control and Prevention: Estimates of future global tuberculosis morbidity and mortality. MMWR 1993, 42:961-964.
6. Centers for Disease Control and Prevention: Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR 1996, 45:921-925.
7. Joint Tuberculosis Committee of the British Thoracic Society: Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998, 53:536-548.
8. Sirgel FA, Botha FJH, Parkin DP, et al.: The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts. A new method of drug assessment. J Antimicrob Chemother 1993, 32:867-875.
9. Jindani A, Aber V, Edwards EA, Mitchison DA: The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980, 121:939-949.
10. Grumbach F, Canetti G, Le Lirzin M: Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results. Tubercle 1969, 50:280-293.
11. Dickinson JM, Mitchison DA: Bactericidal activity in vitro and in guinea-pig of isoniazid, rifampicin and ethambutol. Tubercle 1976, 57:251-258.
12. Dickinson JM, Mitchison DA: Experimental models to explain the high sterilising activity of rifampicin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981, 123:367-371.
13. International Union against Tuberculosis and Lung Disease: Antituberculosis regimens of chemotherapy. Recommendations from the committee on treatment of the IUATLD. Bull Int Union Tuberc Lung Dis 1988, 63:60-64.
14. World Health Organization: Treatment of Tuberculosis: Guidelines for National Programmes [abstract]. 1993.
15. American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Crit Care Med 1994, 149:1359-1374.
16. Singapore Tuberculosis Service/British Medical Research Council: Clinical trial of 6-month and 4-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979, 119:579-585.
17. Tuberculosis Research Centre Madras: Study of chemotherapy regimens of 5 months and 7 months duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 1983, 64:73-91.
18. Mitchison DA, Nunn AJ: Influence of initial resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986, 133:423-430.
19. World Health Organization Tuberculosis Unit: Tuberculosis control and research strategies for the 1990s. Bull World Health Organ 1992, 70:17-21.
20. Schwander S, Rusch-Gerdes S, Mateega A, et al.: A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomised evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuberc Lung Dis 1995, 76:210-218.
21. McGregor MM, Olliaro P, Wolmarans L, et al.: Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Crit Care Med 1996, 154:1462-1467.
22. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P: Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational randomised comparative study versus Rifampicin, Rifabutin Study Group. Tuberc Lung Dis 1994, 75:341-347.
23. Tam CM, Chan SL, Lam CW, et al.: Rifapentine and Isoniazid in the continuation phase of treating pulmonary tuberculosis: initial report. Respir Crit Care Med 1998, 157:1726-1733.
24. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR: Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. N Engl J Med 1994, 328:527-532.
25. Telzak EE, Sepkowitz K, Alpert P, et al.: Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995, 333:907-911.
26. Turett GS, Telzak EE, Torian LV, et al.: Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995, 21:1238-1244.
27. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN: Outcome of MDR-TB patients, 1983-1993. Am J Crit Care Med 1996, 153:317-324.
28. Iseman MD, Madsen LA: Drug-resistant tuberculosis. Clin Chest Med 1989, 10:341-353.
29. Goble M: Drug resistant tuberculosis. Semin Respir Infect 1986, 1:220-229.
30. Iseman MD: Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993, 329:784-791.
31. Wooley CL, Kilburn JO: In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiropiperidyl rifamycin. Am Rev Respir Dis 1982, 126:586-587.
32. Dickinson JM, Mitchison DA: In vitro activity of the new rifamycins against rifampicin resistant M. tuberculosis and MAI-complex mycobacteria. Tubercle 1987, 68:177-182.
33. Pretet S, Lebeaut A, Parrot A, et al.: Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Eur Respir J 1992, 5:680-684.
34. Hong Kong Chest Service/British Medical Research Council: A controlled study of rifabutin and an uncontrolled study of ofloxacin in the treatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuberc Lung Dis 1992, 73:59-67.
35. Perriens JH, St Louis ME, Mukadi YB, et al.: Pulmonary tuberculosis in HIV infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995, 332:779-784.
36. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
37. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996, 334:1011-1017.
38. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced Disease Ritonavir Study Group. Lancet 1997, 351:536-537.
39. Carpenter CC, Fischl M, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
40. BHIVA Guidelines Coordinating Committee: British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
41. Carpenter CCJ, Fischl M, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA panel. JAMA 1998, 280:78-86.
42. Singapore Tuberculosis Service/British Medical Research Council: Clinical trial of 6-month and 4-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. The results up to 30 months. Tubercle 1981, 61:95-102.
43. British Thoracic Society: A controlled trial of 6-month chemotherapy in pulmonary tuberculosis. Final report: results during 36 months after the end of chemotherapy and beyond. Br J Dis Chest 1998, 330-336.
44. Hong Kong Chest Service/British Medical Research Council: First report: controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981, i:171-174.
45. Hong Kong Chest Service/British Medical Research Council: Second report: controlled trial of four thrice-weekly regimens and a daily regimen all given for six months. The results up to 24 months. Tubercle 1982, 63:89-98.
46. Hong Kong Chest Service/British Medical Research Council: Five year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987, 136:1339-1342.
47. Combs DL, O'Brien R, Geiter L: USPHS tuberculosis short-course chemotherapy trial 21. Effectiveness, toxicity and acceptability. The report of final results. Ann Intern Med 1990, 112:397-406.
48. Singapore Tuberculosis Service/British Medical Research Council: Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985, 132:374-378.
49. Singapore Tuberculosis Service/British Medical Research Council: Five year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1988, 137:1147-1150.
50. Snider DE, Graczyk K, Bek E, Rogowski J: Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin and pyrazinamide with or without streptomycin. Am Rev Respir Dis 1984, 130:1091-1094.
51. Hong Kong Chest Service/British Medical Research Council: Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive tuberculosis, including an assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991, 143:700-706.
52. Cohn DL, Catlin BJ, Peterson KL, et al.: A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice weekly, directly observed, and cost effective regimen. Ann Intern Med 1990, 112:407-415.
53. Second East African Study/British Medical Research Council: Controlled trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Am Rev Respir Dis 1976, 114:471-475.
54. Third East African Study/British Medical Research Council: Controlled clinical trial of four short-course chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Tubercle 1980, 61:59-69.
55. Balasubramanian R: Fully intermittent six-month regimens for pulmonary tuberculosis in South India. Ind J Tuberc 1991, 30:51-53.
56. Santha T, Nazareth O, Krishnamurthy MS, et al.: Treatment of pulmonary tuberculosis with short course chemotherapy in South India. Five year follow-up. Tubercle 1989, 70:229-234.
57. Hong Kong Chest Service/British Medical Research Council: Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1978, 118:219-227.
58. Hong Kong Chest Service/British Medical Research Council: Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. Tubercle 1979, 60:201-210.
59. Koopmans PP, Van der Ven AJAM, Vree TB, Van der Meer JWM: Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? AIDS 1995, 9:217-222.
60. Lee BL, Safrin S: Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis 1992, 14:773-779.
61. Chaisson RE, Schecter GF, Theuer CP, et al.: Tuberculosis in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis 1987, 136:570-574.
62. Soriano E, Mallolas J, Gatell JM, et al.: Characteristics of tuberculosis in HIV-infected patients: a case-control study. AIDS 1988, 2:729-732.
63. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell P: Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991, 324:289-294.
64. Pozniak AL, MacLeod GA, Mahari M, Legg W, Weinberg J: The influence of HIV status on single and multiple drug reactions to antituberculous therapy in Africa. AIDS 1992, 6:809-814.
65. Ungo JR, Jones D, Ashkin H, et al.: Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998, 157:1871-1876.
66. Mitchell I, Wendon J, Fitt S, Williams R: Antituberculous therapy and acute liver failure. Lancet 1995, 345:55-56.
67. Absar N, Daneshvar H, Beall G: Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol 1994, 93:1001-1005.
68. Holland CL, Malasky C, Ogunkoya A, Bielory D: Rapid oral desensitization to isoniazid and rifampin. Chest 1990, 98:1518-1519.
69. Matz J, Borish LC, Routes JM, Rosenwasser LJ: Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med 1994, 149:815-817.
70. Peloquin CA, MacPhee AA, Berning SE: Malabsorption of antimycobacterial medications [letter]. N Engl J Med 1993, 329:1122-1123.
71. Patel KB, Belmonte R, Grovo HM: Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995, 332:336-337.
72. Berning SE, Huitt GA, Iseman MD, Peloquin CA: Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 1992, 327:1817-1818.
73. Heylen R, Miller R: Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients. Genitourin Med 1996, 72:237-246.
74. Doble N, Hykin P, Shaw R, et al.: Pharmacokinetic study of the interaction between rifampicin and ketoconazole. J Antimicrob Chemother 1998, 21:633-666.
75. Narang PK, Trapnell CB, Schoenfelder JR, Lavelle JP, Bianchine JR: Fluconazole and enhanced effect of rifabutin prophylaxis [letter, comment]. N Engl J Med 1994, 330:1316-1317.
76. Jorde UP, Horowitz HW, Wormser GP: Significance of drug interactions with rifampin in Pneumocystis carinii pneumonia prophylaxis. Arch Intern Med 1992, 152:23-48.
77. Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K: Reduced serum levels of clarithromycin in patients treated with multi-drug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995, 171:747-750.
78. Djojasaputro M, Mustafo SS, Donatus IA, Santoso B: The effects of doses and pretreatment with rifampin on the elimination kinetics of metronidazole. Eur J Pharmacol 1990, 183:1870-1871.
79. Sadler SM, Blum MR: Relationship between steady state concentrations of atovaquone and the use of various concomitant medications in AIDS patients with PCP. X International Conference on AIDS/IV STD World Congress. Berlin, June 1993 [abstract 504].
80. Gavraffo R, Dellamonica JP, Fournier JP, Lapalus P, Bernard E: The effect of rifampicin on the pharmacokinetics of doxycycline. Infection 1986, 16:297-298.
81. Yu T, Perel J, Berger L, et al.: The effect of the interaction of pyrazinamide and probenicid on urinary uric acid excretion in man. Am J Med 1997, 63:723-728.
82. Heylen R, Miller R: Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: part 2. Genitourin Med 1997, 73:5-11.
83. Li AP, Reith MK, Rasmussen A, et al.: Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 1997, 107:17-30.
84. Perucca E, Grimaldi R, Frigo GM, et al.: Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988, 34:595-599.
85. Burger DM, Meenhorst PL, Koks CHW, Beijnen JH: Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother 1993, 37:1426-1431.
86. Lee BL, Lauber MG, Chambers HF, Gembertoglio J, Delahunty T: The effect of zalcitabine on the pharmacokinetics of isoniazid in HIV-infected patients. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, October 1994 [abstract 3].
87. The Indinavir (MK 639) Pharmacokinetic Study Group Merck Laboratories: Indinavir MK 639 drug interaction studies. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB174].
88. Cato A, Cavanaugh J, Shih Hsu A, Leonard J, Granneman R: The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998, 63:414-421.
89. Polk RE, Israel DS, Patron R, et al.: Pharmacokinetic interaction between 141W94 and rifabutin and rifampicin after multiple dose administration. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 340].
90. Sadler BM, Gillotin C, Chittick GE, Symonds WT: Pharmacokinetic drug interactions with amprenavir. 12th World AIDS Coference. Geneva, June-July 1998 [abstract 12389].
91. Robinson P, Lamson M, Gigliotti M, Myers M: Pharmacokinetic (PK) interaction between nevirapine (NVP) and rifampin (RMP). 12th World AIDS Conference. Geneva, June July 1998 [abstract 60623].
92. Freimuth H: Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. In Antiviral Chemotherapy: New Directions for Clinical Applications and Research, Edited by Mills J, Volberding P, Corey L. New York: Plenum Press; 1996:279-281.
93. Borin MT, Chambers JH, Carel BJ: Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 1997, 61:544-553.
94. Cox SR, Herman BD, Batts DH, Carel BJ, Carberry PA: Delavirdine and rifabutin: pharmatokinetics evaluation in HIV-1 patients with concentration: targeting of celavirdine. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 344].
95. Benedek IH, Joshi A, Fiske WD, et al.: Pharmacokinetic interaction between efavirenz (EFV) and rifampin (RIF) in healthy volunteers. 12th World AIDS Conference. Geneva, June-July 1998 [abstract 42280].
96. Benedek IH, Fiske WD, White SJ, Stevenson D, Joseph JL, Komhauser DM: Pharmacokinetic interaction between multiple doses of efavirenz and rifabutin in healthy volunteers. 36th IDSA, Colorado, USA, 1998 [abstract 461].
97. Goletti D, Weissman D, Jackson RW, et al.: Effect of Mycobacterium tuberculosis in HIV replication: role of immune activation. J Immunol 1996, 157:1271-1278.
98. Centers for Disease Control and Prevention: Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendation. MMWR 1998, 47:1-51.
99. Centers for Disease Control and Prevention: Report of the NIH Panel to Define Principles of Therapy of HIV Infection and guidelines for the use of antiviral agents in HIV-infected adults and adolescents. MMWR 1998, 47:1-82.